Ball & CO Wealth Management Inc. Allogene Therapeutics, Inc. Transaction History
Ball & CO Wealth Management Inc.
- $93.3 Million
- Q1 2025
A detailed history of Ball & CO Wealth Management Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Ball & CO Wealth Management Inc. holds 500 shares of ALLO stock, worth $810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500
Previous 500
-0.0%
Holding current value
$810
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
171Shares Held
143MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$30.3 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$26.6 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$17.6 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.07MShares$13.1 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$11.7 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $233M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...